2015
Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers
Khan SS, Karn T, Symmans WF, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. Breast Cancer Research And Treatment 2015, 149: 789-797. PMID: 25651779, DOI: 10.1007/s10549-015-3277-7.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalAdjuvant chemotherapyEndocrine therapyHigh riskOncotype DXBreast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerRisk categoriesEarly-stage estrogen receptorEndocrine therapy sensitivityGood prognosis patientsER-positive patientsHigh-risk patientsPoor prognosis groupPositive breast cancerLow-risk groupAdjuvant endocrineMultimodality therapyPrognosis patientsRisk patientsEndocrine sensitivityIndependent predictorsPrognosis groupT stage
2012
Agreement in Risk Prediction Between the 21‐Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early‐Stage Estrogen Receptor–Positive Breast Cancer
Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L. Agreement in Risk Prediction Between the 21‐Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early‐Stage Estrogen Receptor–Positive Breast Cancer. The Oncologist 2012, 17: 492-498. PMID: 22418568, PMCID: PMC3336833, DOI: 10.1634/theoncologist.2012-0007.Peer-Reviewed Original ResearchConceptsBreast cancerEstrogen receptorEarly-stage estrogen receptor-positive breast cancerRisk assignmentHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionEstrogen receptor-positive breast cancerReceptor-positive breast cancerIntermediate RS groupLuminal B cancersReceptor 2 expressionLow-risk categoryQuantitative polymerase chain reactionB cancersMore patientsPolymerase chain reactionIntermediate RSLower riskStage IRS groupCancerPAM50Risk categoriesRisk predictionChain reaction